A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

Phase 4CompletedNCT02003534

Allergan376 enrolled

Overview

This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

376

Conditions

Glaucoma, Open-Angle Ocular Hypertension

Interventions

0.15% Brimonidine TartrateDRUG

0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension Exclusion Criteria: * Used Alphagan® in previous 3 months

Locations (1)

Unnamed facility

Shanghai, China

Outcomes

Primary Outcomes

Change From Baseline in Intraocular Pressure (IOP) in the Study Eye

IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).

Time frame: Baseline, Month 3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.